Available Until 9/9/2025
View Cart

Oncology Pharmacy Specialty Home Study Syllabus for Recertification: Module A-D (Cert # L249172)

ACPE Numbers: Various – see listing below
Content Release Date: September 11, 2024
Expiration Dates: September 9, 2025
Activity Type: Application-based
CE Credits: 16 contact hours
Activity Fee: $305 (ASHP member); $440 (non-member) 

The Home Study Syllabus is intended for board-certified pharmacists in need of recertification credit and is designed based on the content outline developed by the Board of Pharmacy Specialties (BPS). NEW in 2024: The Home Study Syllabus is released as a single 16-hour package (see table below). Each activity is designed to assess the learners’ ability to analyze and apply peer-selected contemporary articles to practice.

Learners will be required to review the content of the articles and complete the associated online assessments. The learner must be able to correctly answer the questions based upon their interpretation of the content, as well as “baseline specialty specific knowledge and/or easily retrievable information.” For purposes of this course, “baseline specialty specific knowledge and/or easily retrievable information” is defined as product labeling and well-established standards of practice in the specialty practice.

These activities are part of the ASHP and ACCP professional development program for BCOP recertification approved by the BPS.

ACPE Provider with Commendation logo The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.
ACPE Logo The American College of Clinical Pharmacy is accredited by the Accreditation Council for Pharmacy Education as providers of continuing pharmacy education.

These recertification activities are intended for board-certified pharmacists seeking to update their knowledge and skills in:

  • Adult Sarcomas
  • Bladder, Renal, and Testicular Cancers
  • Breast Cancer
  • Gynecologic Malignancies
  • Hematopoietic Cell Transplantation
  • Lung Cancer
  • Lymphomas
  • Melanoma and Non-Melanoma Skin Cancers
  • Multiple Myeloma
  • Oncology Practice Management
  • Pediatric Malignancies and Supportive Care
  • Pharmacogenomics in Oncology
  • Research Design, Statistics, and Evaluating Oncology Literature

Board-certified pharmacists are eligible to receive up to 16 contact hours of recertification credit for completing this module. To earn recertification credit, learners must review the activity content and successfully complete the online assessments by the deadline.  

ASHP provides an opportunity for remediation. Participants who are unsuccessful with the first assessment attempt may take a second assessment. The second assessment is included at no additional cost. 

BCOP recertification logo

ASHP and ACCP are approved by BPS as providers for the recertification of BCOP.

 

Learning Activity

ACPE Number

Contact Hours (ACPE & BPS)

Assessment Pass Point

Module A: Hematopoietic Cell Transplantation, Multiple Myeloma, Pediatric Malignancies and Supportive Care

0204-9999-24-952-H01-P

4.0

80%
Module B: Oncology Practice Management, Lung Cancer, Breast Cancer, Adult Sarcomas

0204-9999-24-953-H01-P

4.0

75%
Module C: Bladder, Renal Cell, and Testicular Cancers; Gynecologic Malignancies; Pharmacogenomics in Oncology

0204-9999-24-954-H01-P

4.0

83%
Module D: Melanoma and Non-Melanoma Skin Cancers; Lymphomas; Research Design, Statistics, and Evaluating Oncology Literature

0204-9999-24-955-H01-P

4.0

76%

 

Module A: Hematopoietic Cell Transplantation, Multiple Myeloma, Pediatric Malignancies and Supportive Care
ACPE # 0204-9999-24-952-H01-P 

Bolaños-Meade J, Hamadani M, Wu J et al. Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis. N Engl J Med. 2023;388(25):2338-2348. 

Learning Objectives:

  • Describe the study of posttransplant cyclophosphamide for graft-vs.-host disease (GVHD) prophylaxis in allogeneic hematopoietic cell transplantation.
  • Develop recommendations for the use of posttransplant cyclophosphamide in allogeneic hematopoietic cell transplantation for the prevention of GVHD.
  • Select appropriate patients to receive posttransplant cyclophosphamide according to the results of the BMT CTN 1703 trial. 

Sonneveld P, Dimopoulos MA, Boccadoro M et al. Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2023. 2024; 390:301-313. 

Learning Objectives:

  • ​​Describe the PERSEUS study evaluating the addition of daratumumab to bortezomib, lenalidomide, and dexamethasone (VRd) versus VRd for the treatment of newly diagnosed multiple myeloma.​​
  • Develop recommendations for the use of daratumumab-VRd for the treatment of newly diagnosed multiple myeloma.​​
  • ​​​Select appropriate patients to receive daratumumab-VRd according to the results of the PERSEUS study.​​ 

Maese L, Loh ML, Choi MR et al. Recombinant Erwinia asparaginase (JZP458) in acute lymphoblastic leukemia: results from the phase 2/3 AALL1931 study. Blood. 2023;141(7): 704-712. 

Learning Objectives:

  • Describe the study of recombinant Erwinia asparaginase for acute lymphoblastic leukemia (ALL).
  • Develop recommendations for the use of recombinant Erwinia asparaginase in patients with ALL.
  • Select appropriate patients to receive recombinant Erwinia asparaginase therapy according to the results of the study by Maese et al.

 

Module B: Oncology Practice Management, Lung Cancer, Breast Cancer, Adult Sarcomas
ACPE #0204-9999-24-953-H01-P 

Santos ES, Oliver TK, Lacchetti C et al. Drug shortages in oncology: ASCO clinical guidance for alternative treatments. JCO Oncol Pract. 2023;20:19-32. 

Learning Objectives:

  • Describe the clinical practice guidelines from the American Society of Clinical Oncology (ASCO) to navigate the disruption in antineoplastic drug supply caused by drug shortages in patients with cancer.
  • Develop recommendations for the use of institutional strategies to manage drug shortages with anticancer treatment regimens in patients with cancer.
  • Select appropriate patients to receive modified antineoplastic treatment regimens according to the ASCO guidelines for drug shortages in oncology. 

Passaro A, Wang J, Wang Y et al. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study. Ann Oncol. 2023;35: 77-90. 

Learning Objectives:

  • Describe the MARIPOSA-2 trial of amivantamab plus chemotherapy with or without lazertinib for patients with advanced non–small cell lung cancer.
  • Develop recommendations for the use of amivantamab plus chemotherapy with or without lazertinib in patients with advanced non–small cell lung cancer given the results of the MARIPOSA-2 trial.
  • Select appropriate patients to receive amivantamab plus chemotherapy with or without lazertinib given the results of the MARIPOSA-2 trial. 

Moy B, Wolff, AC, Rumble RB et al. Chemotherapy and targeted therapy for endocrine-pretreated or hormone receptor-negative metastatic breast cancer and human epidermal growth factor receptor 2 testing in breast cancer: ASCO Guideline Rapid Recommendation Update Q and A. JCO Oncol Pract. 2023;19:547-550. 

Learning Objectives:

  • Describe the clinical practice guideline from ASCO for the use of sacituzumab govitecan and trastuzumab deruxtecan in the management of endocrine-pretreated or hormone receptor–negative metastatic breast cancer.
  • Develop recommendations for the use of sacituzumab govitecan and trastuzumab deruxtecan in patients with endocrine-pretreated or hormone receptor–negative metastatic breast cancer.
  • Select appropriate patients to receive sacituzumab govitecan and trastuzumab deruxtecan according to the ASCO guideline rapid recommendation update Q and A. 

McCabe C, Wright H, Polson K, Wagner AJ. Supporting patients in the transition to the revised pexidartinib dosing regimen: perspectives from the multidisciplinary clinical and allied health professional team. Orphanet J Rare Dis. 2023;18(1):313. 

Learning Objectives:

  • Develop patient education strategies to communicate the importance of adhering to the revised pexidartinib dosing regimen, including the low-fat meal requirement.
  • Design a multidisciplinary plan to educate patients about how to minimize potential adverse effects.
  • Develop patient education strategies that emphasize the importance of adherence to the Risk Evaluation and Mitigation Strategy (REMS) program, including regular liver function monitoring. 

Module C: Bladder, Renal Cell, and Testicular Cancers; Gynecologic Malignancies; Pharmacogenomics in Oncology
ACPE # 0204-9999-24-954-H01-P 

Loriot Y, Matsubara N, Park SH et al. Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinoma. N Engl J Med. 2023;389:1961-71. 

Learning Objectives:

  • Describe the study by Loriot et al. of erdafitinib compared with chemotherapy for advanced or metastatic urothelial carcinoma.
  • Develop recommendations for the use of erdafitinib in patients with advanced or metastatic urothelial carcinoma.
  • Select appropriate patients to receive erdafitinib according to the results of THOR cohort 1 by Loriot et al. 

Eskander RN, Sill MW, Beffa L et al. Pembrolizumab plus chemotherapy in advanced endometrial cancer. N Engl J Med. 2023;388(23):2159-2170. 

Learning Objectives:

  • Describe the study of pembrolizumab in combination with chemotherapy for advanced or recurrent endometrial cancer.
  • Develop recommendations for the use of pembrolizumab in combination with chemotherapy in patients with advanced or recurrent endometrial cancer.
  • Select appropriate patients to receive pembrolizumab in combination with chemotherapy according to the results of NRG-GY018. 

Hertz DL. Assessment of the clinical utility of pre-treatment DPYD testing for patients receiving fluoropyrimidine chemotherapy. J Clin Oncol. 2022;40:3882-92. 

Baker SD, Bates SE, Brooks GA et al. DPYD testing: time to put patient safety first. J Clin Oncol. 2023;41:2701-2705. 

Learning Objectives:

  • Describe the role of DPYD testing for patients receiving fluoropyrimidine therapy.
  • Develop recommendations for the use of fluoropyrimidines in patients with different DPYD genotypes.
  • Select appropriate patients to receive fluorouracil and capecitabine according to the results of DPYD

Module D: Melanoma and Non-Melanoma Skin Cancers; Lymphomas; Research Design, Statistics, and Evaluating Oncology Literature
ACPE #0204-9999-24-955-H01-P 

Atkins MB, Lee SJ, Chmielowski B et al. Combination dabrafenib and trametinib versus combination nivoluma and ipilimumab for patients with advanced BRAF-mutant melanoma: the DREAMseq trial–ECOG-ACRIN EA613. J Clin Oncol. 2022 Sept 20; 41(2):186-197. 

Learning Objectives:

  • Apply the outcomes of the Atkins et al. trial to patients with melanoma whose treatment plan includes anti–programmed cell death protein 1/cytotoxic T-cell lymphocyte-4 (PD-1/CTLA-4) or BRAF/MEK therapy.
  • Summarize the strengths and weaknesses of the design and methods used in the Atkins et al. trial.
  • Counsel patients with advanced melanoma on the long-term outcomes of immune checkpoint inhibitor or BRAF/MEK therapy. 

Abramson JS, Solomon SR, Arnason J et al. Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study. Blood. 2023;141(14):1675-1684. 

Learning Objectives:

  • Describe the TRANSFORM study of lisocabtagene maraleucel versus the standard of care for the second-line treatment of relapsed or refractory large B-cell lymphoma.
  • Develop recommendations for the use of lisocabtagene maraleucel for the second-line treatment of diffuse large B-cell lymphoma. 

Hunter D, Holmes C. Where medical statistics meets artificial intelligence. N Engl J Med. 2023; 389:1211-1219. 

van der Heijden MS, Sonpavde G, Powles T, et al. Nivolumab plus gemcitabine-cisplatin in advanced urothelial carcinoma. N Engl J Med 2023;389:1778-89.

Learning Objectives:

  • Describe ways in which artificial intelligence (AI) might be used to enhance oncology clinical trials.
  • Interpret an oncology clinical trial evaluating nivolumab in combination for a patient with advanced urothelial carcinoma.
  • Develop a plan to incorporate AI into an oncology clinical trial evaluating nivolumab in combination for advanced urothelial carcinoma.

Full Faculty Bios

John Bossaer, PharmD, BCOP
Professor
ETSU Bill Gatton College of Pharmacy
Johnson City, Tennessee 

Ryan Bycroft, PharmD, BCOP
Clinical Oncology Pharmacist
University of Louisville Hospital, Brown Cancer Center
Louisville, Kentucky 

Courtney C. Cavalieri, PharmD, BCOP*
Clinical Oncology Pharmacist
Huntsman Cancer Institute at the University of Utah
Salt Lake City, Utah 

Karen M. Fancher, PharmD, BCOP*
Associate Professor of Pharmacy Practice
Duquesne University School of Pharmacy
Clinical Pharmacy Specialist, Oncology
University of Pittsburgh Medical Center Passavant
Pittsburgh, Pennsylvania 

Christopher Fausel, PharmD, MHA, BCOP
Director of Pharmacy Precision Genomics
Indiana University Health
Chairman of the Board
Hoosier Cancer Research Network
Indianapolis, Indiana 

Lauren Ice, PharmD, BCOP, BCPS
Pharmacist Supervisor
Corewell Health
Grand Rapids, Michigan 

Alexis R. Jones, PharmD, BCOP, CPP
Gynecologic Oncology Clinical Pharmacist
University of North Carolina Medical Center
Chapel Hill, North Carolina 

Elyse A. MacDonald, PharmD, MS, BCPS
Director, Investigational Drug Service
Stanford Health Care
Palo Alto, California 

Janelle Mann, PharmD, BCOP
Pharmacy Manager
Siteman Cancer Center
Barnes Jewish Hospital
Clinical Oncology Pharmacist
Washington University School of Medicine
St. Louis, Missouri 

Colleen McCabe, PharmD, BCOP
Clinical Oncology Pharmacy Specialist, Sarcoma and Melanoma
Vanderbilt University Medical Center
Nashville, Tennessee 

Donald C. Moore, PharmD, BCPS, BCOP, DPLA, FCCP
Clinical Oncology Pharmacy Manager
Atrium Health Levine Cancer Center
Charlotte, North Carolina 

Anthony J. Perissinotti, PharmD, BCOP*
Hematology Clinical Pharmacist Specialist
University of Michigan
Ann Arbor, Michigan 

Danielle Roman, PharmD, BCOP
Manager, Oncology Clinical Pharmacy Services
Allegheny Health Network
Pittsburgh, Pennsylvania 

Christine M. Walko, PharmD, BCOP, FCCP*
Senior Member, Individualized Cancer Management
Precision Medicine Team Lead
Moffitt Cancer Center
Tampa, Florida 

Jennifer Young, PharmD, BCOP
Clinical Pharmacy Specialist
Cincinnati Children’s Hospital Medical Center
Cincinnati, Ohio 

*Content Matter Experts

Angela T. Cassano, PharmD, BCPS, FASHP
Sue Dombrowski, MS, RPh

Karen Abboud, PharmD, BCPS, BCOP
Megan Adami, PharmD, BCOP
Justin Arnall, PharmD, BCOP
Kimberly Aronoff, BSPharm, PharmD, BCOP
Christine Barrett, PharmD, BCOP
Allison Bass, PharmD, BCOP
Mollie Beck, PharmD, BCOP
Sita Bhatt, PharmD, BCOP
Lauren Blackwell, PharmD, BCOP
Alexandria Blalock Balkcom, PharmD, BCOP
Wendy Boudreau, RPh, BCOP
Janet Bramell, PharmD, BCPS, BCOP
Sara Butler, PharmD, BCOP, BCPS, MHA
Brooke Byrd, PharmD, BCOP
Jill Cassaday, PharmD, BCPS, BCOP
Melvi Chacko, PharmD, BCOP
Ansley Chambers, PharmD, BCOP
Alexis Chapman, PharmD, BCOP
Kelly Chillari, PharmD, BCOP
Michelle Choi, PharmD, BCOP
Jill Comeau, PharmD, BCOP
Jariat Darboe, PharmD, BCPS, BCOP
Jessica Davis, PharmD, BCOP
Lisa Davis, PharmD, BCPS, BCOP
Nicole Davis, PharmD, BCPS, BCOP
Stacy Diao, PharmD, BCOP
Gaity Fair, PharmD, BCOP
Zhou Fang, PharmD
Kristin Gililland, PharmD, BCPS, BCOP
Sara Gordon, PharmD, BCOP
Katherine Guglielmino, PharmD, BCPS, BCOP
Derek Gyori, PharmD, BCOP
Paul Hardy, PharmD, BCPS, BCOP
David Harris, PharmD, BCOP
Ashley Heil, PharmD, BCOP, BCPS
Kristin Herald, PharmD, BCPS, BCOP
Kristina Hesse, PharmD, BCPS, BCOP
Katherine Hill, PharmD, BCOP
Seth Holler, PharmD, BCOP
Phillip Huang, PharmD, BCOP
Urooj Iqbal, MPharm(Hons), BCOP
Elizabeth Jackson, PharmD, BCOP
Mark Jao, PharmD, BCOP
Jocelyn Joseph, PharmD, BCOP
Elizabeth Kelley, PharmD, BCOP, BCPS
Elle Kim, RPh, BCPS, BCOP
Mijeong Kim, PharmD, BCPS, BCOP
Tiffany Knoll, PharmD, MS, BCOP
Kimberley Kolb, RPh BCOP
Tracy Krause, BS, PharmD, BCOP
Matthew Lariviere, PharmD, BCOPChristoph
er Lee, PharmD, BCOP
Crystal Lee, PharmD, BCOP
Jaclyn Leland, PharmD, BCOP
Michael Leung, PharmD BCOP
Whitney Lewis, PharmD, BCOP
Pohung Lin, PharmD, BCPS, BCOP
Jessica Loborec, PharmD, BCOP
Robin Lockhorst, PharmD, BCPS, BCOP
Robert Luschen, PharmD, BCOP
Alixandra Mann, PharmD, BCOP
Diana Mansour, PharmD, BCOP
Stephanie Matta, PharmD, BCOP
Anli McCoy, PharmD, BCOP
William McSkimming, BSPharm, PharmD, BCOP
Christin Molnar, PharmD, BCOP
Christin Molnar, PharmD, BCOP
Katlyn Mulhall, PharmD, BCOP
Noor Naffakh, PharmD, BCOP
Rhobinson Nato, PharmD, BCPS, BCOP
Rhobinson Nato , PharmD, BCPS, BCOP
Sara Nicholas, PharmD, BCOP
Marie-Therese Oyalowo, BS, PharmD, BCOP, FNAP, RN
Grace Park, PharmD, BCOP
Gloria Porcelli, RPh, BCOP
Morgan Randolph, PharmD, BCOP
Mohammad Rattu, PharmD, BCOP, BCPS, BCGP
Mike Reed, BS, BCOP, BCCCP, BCPS
Teresa Rushing, PharmD, BCPS, BCOP
Theresa Ryan, PharmD, BCOP
Stephanie Sanders, PharmD, BCOP, BCCCP
Molly Schmidt, PharmD, BCPS, BCOP, CSP
Zahra Shaghaghi, PharmD, BCOP
Shreya Shah, PharmD, BCOP
Patrick Shin, PharmD, BCPS, BCOP
Anna Shook, PharmD, BCPS, BCOP
Jennifer Showalter, PharmD
Shayna Simon, PharmD, BCOP
Jeffrey Sivik, PharmD, BCOP
Joseph Sleeman, PharmD, BCOP
Carol Stadler, BSPharm, PharmD, BCOP
Amy Stewart, PharmD, BCOP
Randolph Sturgill, PharmD, BCOP
Anna Sweet, PharmD, BCOP
Tara Thompson, PharmD, MBA, BCPS, BCOP
Katelyn Toeniskoetter, PharmD, BCOP
Sorana Ursu, PharmD, BCOP
Eric Vertin, PharmD, BCPS, BCOP
Chad Weber, PharmD, BCOP
Alex Wen, PharmD
Guolin Wen, PharmD
Taylor White, PharmD, BCOP
Brenda Winger, PharmD, BCPS, BCOP
Lily Yan, PharmD, BCOP
Avani Yenamandra, PharmD, BCOP
Barbara Yim, PharmD, BCOP

In accordance with our accreditor’s Standards of Integrity and Independence in Accredited Continuing Education, ASHP requires that all individuals in control of content disclose all financial relationships with ineligible companies. An individual has a relevant financial relationship if they have had a financial relationship with an ineligible company in any dollar amount in the past 24 months and the educational content that the individual controls is related to the business lines or products of the ineligible company.

An ineligible company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The presence or absence of relevant financial relationships will be disclosed to the activity audience. 

The following persons in control of this activity’s content have relevant financial relationships:

  • Karen Fancher: Advisory Board, AstraZeneca; Advisory Board and Speakers' Bureau, BTG Specialty Pharmaceuticals
  • Donald Moore: Advisory Board, Janssen
  • Alexis Jones: Consultant, Eisai
  • Anthony Perissinotti: Consultant and Advisory Board, BeiGene, Pfizer, Servier, Sanofi Aventis; Advisory Board, Abbvie, Janssen
  • Christopher Fausel: Research Grant, Pfizer, Foundation Medicine, Genentech 

All other persons in control of content do not have any relevant financial relationships with an ineligible company. 

As required by the Standards of Integrity and Independence in Accredited Continuing Education, all relevant financial relationships have been mitigated prior to the CPE activity.

Activities consist of educational materials, assessments, and activity evaluations. In order to receive continuing pharmacy education credit, learners must:

  • Complete the attestation statement
  • Review all content
  • Complete and pass the assessments
  • Complete the evaluations

Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity. 

ASHP collaborates with ACCP on oncology pharmacy activities.